Zhang Lei, Huang Wenhua, Zhang Shengwei, Li Qian, Wang Ye, Chen Ting, Jiang Hua, Kong Decong, Lv Qingyu, Zheng Yuling, Ren Yuhao, Liu Peng, Jiang Yongqiang, Chen Ying
College of Life Science, Yantai University, Yantai, China.
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
Front Microbiol. 2022 May 17;13:858777. doi: 10.3389/fmicb.2022.858777. eCollection 2022.
Urinary tract infections (UTIs) are among the most common acquired bacterial infections in humans. The current gold standard method for identification of uropathogens in clinical laboratories is cultivation. However, culture-based assays have substantial drawbacks, including long turnaround time and limited culturability of many potential pathogens. Nanopore sequencing technology can overcome these limitations and detect pathogens while also providing reliable predictions of drug susceptibility in clinical samples. Here, we optimized a metagenomic nanopore sequencing (mNPS) test for pathogen detection and identification in urine samples of 76 patients with acute uncomplicated UTIs. We first used twenty of these samples to show that library preparation by the PCR Barcoding Kit (PBK) led to the highest agreement of positive results with gold standard clinical culture tests, and enabled antibiotic resistance detection in downstream analyses. We then compared the detection results of mNPS with those of culture-based diagnostics and found that mNPS sensitivity and specificity of detection were 86.7% [95% confidence interval (CI), 73.5-94.1%] and 96.8% (95% CI, 82.4-99.9%), respectively, indicating that the mNPS method is a valid approach for rapid and specific detection of UTI pathogens. The mNPS results also performed well at predicting antibiotic susceptibility phenotypes. These results demonstrate that our workflow can accurately diagnose UTI-causative pathogens and enable successful prediction of drug-resistant phenotypes within 6 h of sample receipt. Rapid mNPS testing is thus a promising clinical diagnostic tool for infectious diseases, based on clinical urine samples from UTI patients, and shows considerable potential for application in other clinical infections.
尿路感染(UTIs)是人类最常见的获得性细菌感染之一。临床实验室中目前用于鉴定尿路病原体的金标准方法是培养。然而,基于培养的检测方法存在诸多缺点,包括周转时间长以及许多潜在病原体的可培养性有限。纳米孔测序技术可以克服这些局限性,检测病原体,同时还能对临床样本中的药物敏感性提供可靠预测。在此,我们优化了一种宏基因组纳米孔测序(mNPS)检测方法,用于检测和鉴定76例急性单纯性UTI患者尿液样本中的病原体。我们首先使用其中20个样本表明,使用PCR条形码试剂盒(PBK)进行文库制备可使阳性结果与金标准临床培养检测的一致性最高,并能在下游分析中检测抗生素耐药性。然后,我们将mNPS的检测结果与基于培养的诊断方法的结果进行比较,发现mNPS检测的敏感性和特异性分别为86.7% [95%置信区间(CI),73.5 - 94.1%]和96.8%(95% CI,82.4 - 99.9%),这表明mNPS方法是快速、特异性检测UTI病原体的有效方法。mNPS结果在预测抗生素敏感性表型方面也表现良好。这些结果表明,我们的工作流程能够准确诊断UTI致病病原体,并能在收到样本后6小时内成功预测耐药表型。因此,基于UTI患者的临床尿液样本,快速mNPS检测是一种很有前景的传染病临床诊断工具,在其他临床感染中也显示出相当大的应用潜力。